Home » Posts tagged 'drug pricing'

Tag Archives: drug pricing

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman and Anupam Jena discuss the challenges of value-based pricing and health technology assessments. (more…)

Value-Based Pricing For Pharmaceuticals In The Trump Administration

The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.  (more…)

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

Why Academics Consulting with Industry on Health Care May be an Idea Whose Time has Come

At a time of deep political division, an academic approach to policy making has never been more important. (more…)

Election verdict: Pharma Needs a New Prescription

Dana Goldman and Darius Lakdawalla provide a policy prescription list for the pharmaceutical industry aimed at improving access for patients today without discouraging investments into tomorrow’s medical innovations.  (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

Can Shopping Around for Prescriptions Save Money?

Research conducted by USC Price MPP students found huge variation in prescription drug prices when shopping around at pharmacies in the LA area.  Based on their experience, they recommend four strategies consumers should use to get the lowest price. (more…)

What the Candidates Don’t Get About Drug Prices

If you are like me, you are watching with relish the presidential debates on both the Republican and Democratic side. Sometimes, amid the reality show-type theatrics, they actually substantive discussions about issues like Social Security, (more…)

A New Line of Specialty Drugs: PCSK9 Inhibitors (Part 2)

This fall, a new line of specialty drugs will hit the market- PCSK9 inhibitors.  PCSK9 inhibitors are a new class of drugs used to lower LDL (bad) cholesterol levels through stifling a protein (PCSK9). The drug is injected once or twice a month and is (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook